Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

37.20 +0.58 (+1.58%)
Streaming Delayed Price Updated: 12:15 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
38 39 Next >
Options Trader Betting On GSK Stock Rising Heading Into 2023
Options traders are making big bets on the upside for healthcare, particularly in shares of GSK plc (NYSE: GSK). 
Via Benzinga
Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders
Via Benzinga
Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
New data at ASH underscore the potential for durable, clinically important responses with momelotinib for myelofibrosis patients
From GSK plc
Via Business Wire
GSK's Debt Overview
Over the past three months, shares of GSK Inc. (NYSE:GSK) moved higher by 19.05%. When understanding a companies price change over a time period like 3 months, it could be helpful to look at its... 
Via Benzinga
GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients
Via Benzinga
GSK Limits Second-Line Maintenance Use Of Its Ovarian Cancer Drug To Some Populations
Via Benzinga
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months. 
Via MarketBeat
France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine
Via Benzinga
GSK's Jemperli/Chemo Combo Shows Response Rate Of 46% In Head-To-Head Lung Cancer Trial
Via Benzinga
Meta Criticized For Providing Extra Protection To Certain Users, Twitter HQ Bedrooms Under Regulatory Scrutiny, Juul Settles Over 5,000 Lawsuits: Top Stories Wednesday, Dec. 07
Benzinga 
Via Benzinga
Why Vir Biotechnology Jumped Nearly 19% Today
A COVID-19 partnership with a major drugmaker is producing more fruit than expected. 
Via The Motley Fool
Relief To Pfizer, Sanofi As US Dismisses Several Lawsuits Associated With Zantac
Via Benzinga
These 3 Stocks Escaped Tuesday's Market Downdraft
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies. 
Via The Motley Fool
Why GSK Plc And Sanofi SA Stock Are Shooting Higher
Shares of GSK plc (NYSE: GSK) and Sanofi SA (NASDAQ: SNY) are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit. 
Via Benzinga
Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
From Singapore Economic Development Board (EDB)A*STAR
Via ACN Newswire
Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
Researchers Working On Universal mRNA-Influenza Vaccine Aiming For Baseline Immune Memory For Diverse Strains
Researchers are working on an experimental pan-influenza vaccine based on the famed mRNA technology to provide broad protection. 
Via Benzinga
After Disappointing Confirmatory Study, GSK To Withdraw Approved Blood Cancer Drug In US
Via Benzinga
Dividend Income Update October 2022
It’s dividend income update time. One of my favorite times of the month as I get to review my previous month of passive income received from my dividend income portfolio. 
Via Talk Markets
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
Via Benzinga
Peering Into GSK's Recent Short Interest
GSK's (NYSE:GSK) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 13.36 million shares sold short, which is 0.7% of all regular shares that are... 
Via Benzinga
Daily Stock Analysis: GSK plc
By my dogcatcher ideal, this is a likely time to buy GSK plc shares based on their dividends for the coming year 2022-23. 
Via Talk Markets
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
GSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard Care
Via Benzinga
Week in Review: CBC Plans $137 Million Shanghai Biopharma Complex
Deals, financings, trials and approvals in Chinese biotech/biopharma this week. 
Via Talk Markets
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates. 
Via Investor's Business Daily
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.